Nanoparticulate drug delivery in pregnancy: Placental passage and fetal exposure

Current Pharmaceutical Biotechnology

Volumn 12, Issue 5, 2011, Pages 731-742

  Menezes, Vinith ^a   Malek, Antoine ^b   Keelan, Jeffrey A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fetus; Nanoparticle; Pharmaceutical; Placenta; Pregnancy; Uptake

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; CADMIUM; FULLERENE DERIVATIVE; GOLD NANOPARTICLE; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; TITANIUM DIOXIDE;

COGNITIVE DEFECT; DRUG DELIVERY SYSTEM; EPILEPSY; EXHAUST GAS; FETOPLACENTAL UNIT; FETOTOXICITY; HUMAN; MALFORMATION SYNDROME; NANOTOXICOLOGY; NONHUMAN; PARTICLE SIZE; PERMEABILITY; PLACENTA; PREGNANCY; PRENATAL DRUG EXPOSURE; REVIEW; RISK BENEFIT ANALYSIS; RODENT; SAFETY; TOXICITY TESTING;

RODENTIA;

EID: 79955621885     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795471010     Document Type: Review

References (139)

1. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55(3), 329-347.
2. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14(5), 1310-1316.
3. Salata, O. Applications of nanoparticles in biology and medicine. J. Nanobiotechnology, 2004, 2(1), 3.
4. Oberdörster, G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med., 2010, 267(1), 89-105.
5. Menjoge, A. R.; Kannan, R. M.; Tomalia, D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today, 2010, 15(5-6), 171-185.
6. Olivier, J.C. Drug transport to brain with targeted nanoparticles. NeuroRx, 2005, 2(1), 108-119.
7. Hardman, R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect., 2006, 114(2), 165-172.
8. Hoet, P.H.; Brüske-Hohlfeld, I.; Salata, O.V. Nanoparticles-known and unknown health risks. J. Nanobiotechnology, 2004, 2(1), 12.
9. Garnett, M.C.; Kallinteri, P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. (Lond.), 2006, 56(5), 307-311.
10. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., 2008, 5(4), 505-515.
11. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53(2), 283-318.
12. Chan, V.S. Nanomedicine: An unresolved regulatory issue. Regul. Toxicol. Pharmacol., 2006, 46(3), 218-224.
13. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces, 2010, 75(1), 1-18.
14. Bhardwaj, V.; Ankola, D.D.; Gupta, S.C.; Schneider, M.; Lehr, C.M.; Kumar, M.N. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm. Res., 2009, 26(11), 2495-2503.
15. Galindo-Rodriguez, S.A.; Allemann, E.; Fessi, H.; Doelker, E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst., 2005, 22(5), 419-464.
16. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
17. Balogh, L.; Nigavekar, S.S.; Nair, B.M.; Lesniak, W.; Zhang, C.; Sung, L.Y.; Kariapper, M.S.; El-Jawahri, A.; Llanes, M.; Bolton, B.; Mamou, F.; Tan, W.; Hutson, A.; Minc, L.; Khan, M.K. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine, 2007, 3(4), 281-296.
18. Lewin, M.; Carlesso, N.; Tung, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol., 2000, 18(4), 410-414.
19. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5(4), 487-495.
20. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603.
21. Frank, M.M.; Fries, L.F. The role of complement in inflammation and phagocytosis. Immunol. Today, 1991, 12(9), 322-326.
22. Zámecník, J.; Vargová, L.; Homola, A.; Kodet, R.; Syková, E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol. Appl. Neurobiol., 2004, 30(4), 338-350.
23. Torchilin, V.P.; Levchenko, T.S.; Rammohan, R.; Volodina, N.; Papahadjopoulos-Sternberg, B.; D'Souza, G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl Acad. Sci. U S A, 2003, 100(4), 1972-1977.
24. Faure, A.C.; Dufort, S.; Josserand, V.; Perriat, P.; Coll, J.L.; Roux, S.; Tillement, O. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small, 2009, 5(22), 2565-2575.
25. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 2009, 8(2), 129-138.
26. Auguste, D.T.; Furman, K.; Wong, A.; Fuller, J.; Armes, S.P.; Deming, T.J.; Langer, R. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J. Control. Release, 2008, 130(3), 266-274.
27. Isobe, H.; Nakanishi, W.; Tomita, N.; Jinno, S.; Okayama, H.; Nakamura, E. Nonviral gene delivery by tetraamino fullerene. Mol. Pharm., 2006, 3(2), 124-134.
28. Bridot, J.L.; Faure, A.C.; Laurent, S.; Rivière, C.; Billotey, C.; Hiba, B.; Janier, M.; Josserand, V.; Coll, J.L.; Elst, L.V.; Muller, R.; Roux, S.; Perriat, P.; Tillement, O. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J. Am. Chem. Soc., 2007, 129(16), 5076-5084.
29. Ballou, B.; Lagerholm, B.C.; Ernst, L.A.; Bruchez, M.P.; Waggoner, A.S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15(1), 79-86.
30. Schroeder, A.; Levins, C.G.; Cortez, C.; Langer, R.; Anderson, D.G. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med., 2010, 267(1), 9-21.
31. Souto, E.B.; Müller, R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol., 2010, 197, 115-141.
32. Love, K.T.; Mahon, K.P.; Levins, C.G.; Whitehead, K.A.; Querbes, W.; Dorkin, J.R.; Qin, J.; Cantley, W.; Qin, L.L.; Racie, T.; Frank-Kamenetsky, M.; Yip, K.N.; Alvarez, R.; Sah, D.W.; de Fougerolles, A.; Fitzgerald, K.; Koteliansky, V.; Akinc, A.; Langer, R.; Anderson, D.G. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. U S A, 2010, 107(5), 1864-1869.
33. Tan, M.L.; Choong, P.F.; Dass, C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides, 2010, 31(1), 184-193.
34. Quan, C.Y.; Wei, H.; Sun, Y.X.; Cheng, S.X.; Shen, K.; Gu, Z.W.; Zhang, X.Z.; Zhuo, R.X. Polyethyleneimine modified biocompatible poly(N-isopropylacrylamide)-based nanogels for drug delivery. J. Nanosci. Nanotechnol., 2008, 8(5), 2377-2384.
35. Song, W.J.; Du, J.Z.; Sun, T.M.; Zhang, P.Z.; Wang, J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small, 2010, 6(2), 239-246.
36. Xia, T.; Kovochich, M.; Liong, M.; Meng, H.; Kabehie, S.; George, S.; Zink, J.I.; Nel, A.E. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano, 2009, 3(10), 3273-3286.
37. Zhang, S.; Wang, G.; Lin, X.; Chatzinikolaidou, M.; Jennissen, H.P.; Laub, M.; Uludaǧ, H. Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol. Prog., 2008, 24(4), 945-956.
38. Panyam, J.; Zhou, W.Z.; Prabha, S.; Sahoo, S.K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J., 2002, 16(10), 1217-1226.
39. Bazile, D.; Prud'homme, C.; Bassoullet, M.T.; Marlard, M.; Spenlehauer, G.; Veillard, M. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci., 1995, 84(4), 493-498.
40. Fang, C.; Shi, B.; Pei, Y.Y.; Hong, M.H.; Wu, J.; Chen, H.Z. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci., 2006, 27(1), 27-36.
41. Heidel, J.D.; Yu, Z.; Liu, J.Y.; Rele, S.M.; Liang, Y.; Zeidan, R.K.; Kornbrust, D.J.; Davis, M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U S A, 2007, 104(14), 5715-5721.
42. Steinmetz, N.F.; Hong, V.; Spoerke, E.D.; Lu, P.; Breitenkamp, K.; Finn, M.G.; Manchester, M. Buckyballs meet viral nanoparticles: candidates for biomedicine. J. Am. Chem. Soc., 2009, 131(47), 17093-17095.
43. Partha, R.; Conyers, J.L. Biomedical applications of functionalized fullerene-based nanomaterials. Int. J. Nanomed., 2009, 4, 261-275.
44. Partha, R.; Mitchell, L.R.; Lyon, J.L.; Joshi, P.P.; Conyers, J.L. Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery. ACS Nano, 2008, 2(9), 1950-1958.
45. Maeda-Mamiya, R.; Noiri, E.; Isobe, H.; Nakanishi, W.; Okamoto, K.; Doi, K.; Sugaya, T.; Izumi, T.; Homma, T.; Nakamura, E. In vivo gene delivery by cationic tetraamino fullerene. Proc. Natl. Acad. Sci. USA, 2010, 107(12), 5339-5344.
46. Akinc, A.; Querbes, W.; De, S.; Qin, J.; Frank-Kamenetsky, M.; Jayaprakash, K.N.; Jayaraman, M.; Rajeev, K.G.; Cantley, W.L.; Dorkin, J.R.; Butler, J.S.; Qin, L.; Racie, T.; Sprague, A.; Fava, E.; Zeigerer, A.; Hope, M.J.; Zerial, M.; Sah, D.W.; Fitzgerald, K.; Tracy, M.A.; Manoharan, M.; Koteliansky, V.; Fougerolles, A.D.; Maier, M.A. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther., 2010, 18(7), 1357-1364.
47. Estévez, M.C.; Huang, Y.F.; Kang, H.; O'Donoghue, M.B.; Bamrungsap, S.; Yan, J.; Chen, X.; Tan, W. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Methods Mol. Biol., 2010, 624, 235-248.
48. Hosta-Rigau, L.; Olmedo, I.; Arbiol, J.; Cruz, L.J.; Kogan, M.J.; Albericio, F. Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug. Chem., 2010, 21(6), 1070-1078.
49. Jain, N.K.; Jain, S.K. Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS PharmSciTech., 2010, 11(2), 686-697.
50. Kularatne, S.A.; Low, P.S. Targeting of nanoparticles: folate receptor. Methods Mol. Biol., 2010, 624, 249-265.
51. Pan, J.; Liu, Y.; Feng, S.S. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine, (Lond.) 2010, 5(3), 347-360.
52. Rothdiener, M.; Beuttler, J.; Messerschmidt, S.K.; Kontermann, R.E. Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol. Biol., 2010, 624, 295-308.
53. Katz, E.; Willner, I. Integrated nanoparticle-biomolecule hybrid systems: synthesis, properties, and applications. Angew. Chem. Int. Ed. Engl., 2004, 43(45), 6042-6108.
54. Oberdörster, G.; Oberdörster, E.; Oberdörster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 2005, 113(7), 823-839.
55. Nemmar, A.; Melghit, K.; Ali, B.H. The acute proinflammatory and prothrombotic effects of pulmonary exposure to rutile TiO2 nanorods in rats. Exp. Biol. Med., (Maywood) 2008, 233(5), 610-619.
56. Nemmar, A.; Al-Maskari, S.; Ali, B.H.; Al-Amri, I.S. Cardiovascular and lung inflammatory effects induced by systemically administered diesel exhaust particles in rats. Am. J. Physiol. Lung Cell. Mol. Physiol., 2007, 292(3), L664-L670.
57. Geiser, M.; Rothen-Rutishauser, B.; Kapp, N.; Schürch, S.; Kreyling, W.; Schulz, H.; Semmler, M.; Im Hof, V.; Heyder, J.; Gehr, P. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect., 2005, 113(11), 1555-1560.
58. Rothen-Rutishauser, B.M.; Schürch, S.; Haenni, B.; Kapp, N.; Gehr, P. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ. Sci. Technol., 2006, 40(14), 4353-4359.
59. Saunders, M. Transplacental transport of nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1(6), 671-684.
60. Ono, N.; Oshio, S.; Niwata, Y.; Yoshida, S.; Tsukue, N.; Sugawara, I.; Takano, H.; Takeda, K. Detrimental effects of prenatal exposure to filtered diesel exhaust on mouse spermatogenesis. Arch. Toxicol., 2008, 82(11), 851-859.
61. Watanabe, N.; Oonuki, Y. Inhalation of diesel engine exhaust affects spermatogenesis in growing male rats. Environ. Health Perspect., 1999, 107(7), 539-544.
62. Yokota, S.; Mizuo, K.; Moriya, N.; Oshio, S.; Sugawara, I.; Takeda, K. Effect of prenatal exposure to diesel exhaust on dopaminergic system in mice. Neurosci. Lett., 2009, 449(1), 38-41.
63. Yoshida, S.; Hiyoshi, K.; Oshio, S.; Takano, H.; Takeda, K.; Ichinose, T. Effects of fetal exposure to carbon nanoparticles on reproductive function in male offspring. Fertil. Steril., 2010, 93(5), 1695-1699.
64. Yoshida, S.; Ono, N.; Tsukue, N.; Oshio, S.; Umeda, T.; Takano, H.; Takeda, K. In utero exposure to diesel exhaust increased accessory reproductive gland weight and serum testosterone concentration in male mice. Environ. Sci., 2006, 13(3), 139-147.
65. Takeda, K.; Tsukue, N.; Yoshida, S. Endocrine-disrupting activity of chemicals in diesel exhaust and diesel exhaust particles. Environ. Sci., 2004, 11(1), 33-45.
66. Suzuki, T.; Oshio, S.; Iwata, M.; Saburi, H.; Odagiri, T.; Udagawa, T.; Sugawara, I.; Umezawa, M.; Takeda, K. In utero exposure to a low concentration of diesel exhaust affects spontaneous locomotor activity and monoaminergic system in male mice. Part. Fibre Toxicol., 2010, 7, 7.
67. Nyland, J.F.; Silbergeld, E.K. A nanobiological approach to nanotoxicology. Hum. Exp. Toxicol., 2009, 28(6-7), 393-400.
68. Vandenbroucke, R.E.; De Geest, B.G.; Bonné, S.; Vinken, M.; Van Haecke, T.; Heimberg, H.; Wagner, E.; Rogiers, V.; De Smedt, S.C.; Demeester, J.; Sanders, N.N. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). J. Gene Med., 2008, 10(7), 783-794.
69. Page, K.R. The physiology of human placenta. UCL Press Limited: London, 1993, pp. 164-169.
70. Schneider, H. The role of the placenta in nutrition of the human fetus. Am. J. Obstet. Gynecol., 1991, 164(4), 967-973.
71. Syme, M.R.; Paxton, J.W.; Keelan, J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet., 2004, 43(8), 487-514.
72. Christensen, H.N.; Streicher, J.A. Association between rapid growth and elevated cell concentrations of amino acids; in fetal tissues. J. Biol. Chem., 1948, 175(1), 95-100.
73. Evseenko, D.; Paxton, J.W.; Keelan, J.A. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin. Drug Metab. Toxicol., 2006, 2(1), 51-69.
74. Firth, J.A.; Leach, L. Not trophoblast alone: a review of the contribution of the fetal microvasculature to transplacental exchange. Placenta, 1996, 17(2-3), 89-96.
75. Eaton, B.M.; Leach, L.; Firth, J.A. Permeability of the fetal villous microvasculature in the isolated perfused term human placenta. J. Physiol., 1993, 463, 141-155.
76. Boyd, R.D.; Canning, J.F.; Stacey, T.E.; Ward, R.H.; Weedon, A.P. Volumes of distribution of sodium and albumin in the sheep placenta. J. Physiol., 1983, 336, 13-26.
77. Thornburg, K.L.; Faber, J.J. The steady state concentration gradients of an electron-dense marker (ferritin in the three-layered hemochorial placenta of the rabbit. J. Clin. Invest., 1976, 58(4), 912-925.
78. van der Aa, E.M.; Peereboom-Stegeman, J.H.; Noordhoek, J.; Gribnau, F.W.; Russel, F.G. Mechanisms of drug transfer across the human placenta. Pharm. World Sci., 1998, 20(4), 139-148.
79. Sastry, B.V. Techniques to study human placental transport. Adv. Drug Deliv. Rev., 1999, 38(1), 17-39.
80. Ward, R.M. Drug therapy of the fetus. J. Clin. Pharmacol., 1993, 33(9), 780-789.
81. Malek, A.; Sager, R.; Schneider, H. Transport of proteins across the human placenta. Am. J. Reprod. Immunol., 1998, 40(5), 347-351.
82. Boyd, J.D.; Hamilton, W.J. Development and structure of the human placenta from the end of the 3rd month of gestation. J. Obstet. Gynaecol. Br. Commonw., 1967, 74(2), 161-226.
83. Leiser, R.; Kaufmann, P. Placental structure: in a comparative aspect. Exp. Clin. Endocrinol., 1994, 102(3), 122-134.
84. Mossman, H.W. In: Contributions to Embryology; Carnegie Institute: Washington, 1937; Vol. 26, pp. 129-246.
85. Enders, A.C.; Blankenship, T.N. Comparative placental structure. Adv. Drug Deliv. Rev., 1999, 38(1), 3-15.
86. Carter, A.M. Animal models of human placentation--a review. Placenta, 2007, 28(Suppl A), S41-S47.
87. Botting, J. The history of thalidomide. Drug News Perspect., 2002, 15(9), 604-611.
88. Carney, E.W.; Scialli, A.R.; Watson, R.E.; DeSesso, J.M. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Br. Defects Res. C Embryo Today, 2004, 72(4), 345-360.
89. Malek, A.; Sager, R.; Lang, A.B.; Schneider, H. Protein transport across the in vitro perfused human placenta. Am. J. Reprod. Immunol., 1997, 38(4), 263-271.
90. Brambell, F.W.R. In: The Transmission of Passive Immunity from Mother to Young. North Holland Publishing Company Amsterdam, 1970.
91. Kim, J.; Mohanty, S.; Ganesan, L.P.; Hua, K.; Jarjoura, D.; Hayton, W.L.; Robinson, J.M.; Anderson, C.L. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J. Immunol., 2009, 182(5), 2583-2589.
92. Pratten, M.K.; Lloyd, J.B. Uptake of microparticles by rat visceral yolk sac. Placenta, 1997, 18(7), 547-552.
93. Nau, H. Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect., 1986, 70, 113-129.
94. Myllynen, P.; Pasanen, M.; Vähäkangas, K. The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 331-346.
95. Schneider, H.; Miller, R.K. Receptor-mediated uptake and transport of macromolecules in the human placenta. Int. J. Dev. Biol., 2010, 54(2-3), 367-375.
96. Gedeon, C.; Koren, G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta, 2006, 27(8), 861-868.
97. Ganapathy, V.; Prasad, P.D.; Ganapathy, M.E.; Leibach, F.H. Placental transporters relevant to drug distribution across the maternal-fetal interface. J. Pharmacol. Exp. Ther., 2000, 294(2), 413-420.
98. Ganapathy, V.; Prasad, P.D. Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol., 2005, 207(2 Suppl), 381-387.
99. Aye, I.L.; Waddell, B.J.; Mark, P.J.; Keelan, J.A. Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity. Biochim. Biophys. Acta, 2010, 1801(9), 1013-1024.
100. Perez-D'Gregorio, R.E.; Miller, R.K. Transport and endogenous release of vitamin B12 in the dually perfused human placenta. J. Pediatr., 1998, 132(3 Pt 2), S35-S42.
101. Palinski, W. Maternal-fetal cholesterol transport in the placenta: good, bad, and target for modulation. Circ. Res., 2009, 104(5), 569-571.
102. Leach, L.; Eaton, B.M.; Firth, J.A.; Contractor, S.F. Immunocytochemical and labelled tracer approaches to uptake and intracellular routing of immunoglobulin-G (IgG) in the human placenta. Histochem. J., 1991, 23(10), 444-449.
103. Leach, L.; Firth, J.A. Structure and permeability of human placental microvasculature. Microsc. Res. Tech., 1997, 38(1-2), 137-144.
104. Bright, N.A.; Ockleford, C.D.; Anwar, M. Ontogeny and distribution of Fc gamma receptors in the human placenta. Transport or immune surveillance? J. Anat., 1994, 184(Pt 2), 297-308.
105. Mishima, T.; Kurasawa, G.; Ishikawa, G.; Mori, M.; Kawahigashi, Y.; Ishikawa, T.; Luo, S.S.; Takizawa, T.; Goto, T.; Matsubara, S.; Takeshita, T.; Robinson, J.M.; Takizawa, T. Endothelial expression of Fc gamma receptor IIb in the full-term human placenta. Placenta, 2007, 28(2-3), 170-174.
106. May, K.; Grube, M.; Malhotra, I.; Long, C.A.; Singh, S.; Mandaliya, K.; Siegmund, W.; Fusch, C.; Schneider, H.; King, C.L. Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model. PLoS One, 2009, 4(11), e7986.
107. Ockleford, C.D.; Whyte, A. Differeniated regions of human placental cell surface associated with exchange of materials between maternal and foetal blood: coated vesicles. J. Cell Sci., 1977, 25, 293-312.
108. Pearse, B.M. Coated vesicles from human placenta carry ferritin, transferrin, and immunoglobulin G. Proc. Natl. Acad. Sci. U S A, 1982, 79(2), 451-455.
109. Wilson, J.M.; King, B.F. Transport of horseradish peroxidase across monkey trophoblastic epithelium in coated and uncoated vesicles. Anat. Rec., 1985, 211(2), 174-183.
110. Contractor, S.F.; Krakauer, K. Pinocytosis and intracellular digestion of 125I-labelled haemoglobin by trophoblastic cells in tissue culture in the presence and absence of serum. J. Cell Sci., 1976, 21(3), 595-607.
111. Lambot, N.; Lybaert, P.; Boom, A.; Delogne-Desnoeck, J.; Vanbellinghen, A.M.; Graff, G.; Lebrun, P.; Meuris, S. Evidence for a clathrin-mediated recycling of albumin in human term placenta. Biol. Reprod., 2006, 75(1), 90-97.
112. Kertschanska, S.; Stulcová, B.; Kaufmann, P.; Stulc, J. Distensible transtrophoblastic channels in the rat placenta. Placenta, 2000, 21(7), 670-677.
113. Kertschanska, S.; Kosanke, G.; Kaufmann, P. Is there morphological evidence for the existence of transtrophoblastic channels in human placental villi? Placenta, 1994, 15(Suppl 1), 581-596.
114. Kertschanska, S.; Kosanke, G.; Kaufmann, P. Pressure dependence of so-called transtrophoblastic channels during fetal perfusion of human placental villi. Microsc. Res. Tech., 1997, 38(1-2), 52-62.
115. Stulc, J. Extracellular transport pathways in the haemochorial placenta. Placenta, 1989, 10(1), 113-119.
116. Malek, A.; Sager, R.; Eckardt, K.U.; Bauer, C.; Schneider, H. Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system. Pflugers Arch., 1994, 427(1-2), 157-161.
117. Fujimoto, A.; Tsukue, N.; Watanabe, M.; Sugawara, I.; Yanagisawa, R.; Takano, H.; Yoshida, S.; Takeda, K. Diesel exhaust affects immunological action in the placentas of mice. Environ. Toxicol., 2005, 20(4), 431-440.
118. Sugamata, M.; Ihara, T.; Takano, H.; Oshio, S.; Takeda, K. Maternal diesel exhaust exposure damages newborn murine brains. J. Health Sci., 2006, 52(1), 82-84.
119. Takeda, K.; Suzuki, K.; Ishihara, A.; Kubo-Irie, M.; Fujimoto, R.; Tabata, M.; Oshio, S.; Nihei, Y.; Ihara, T.; Sugamata, M. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J. Health Sci., 2009, 55(1), 95-102.
120. Shimizu, M.; Tainaka, H.; Oba, T.; Mizuo, K.; Umezawa, M.; Takeda, K. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse. Part. Fibre Toxicol., 2009, 6(1), 20.
121. Tsuchiya, T.; Oguri, I.; Yamakoshi, Y.N.; Miyata, N. Novel harmful effects of [60]fullerene on mouse embryos in vitro and in vivo. FEBS Lett., 1996, 393(1), 139-145.
122. Chu, M.; Wu, Q.; Yang, H.; Yuan, R.; Hou, S.; Yang, Y.; Zou, Y.; Xu, S.; Xu, K.; Ji, A.; Sheng, L. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small, 2010, 6(5), 670-678.
123. Semmler-Behnke, M.; Kreyling, W.G.; Lipka, J.; Fertsch, S.; Wenk, A.; Takenaka, S.; Schmid, G.; Brandau, W. Biodistribution of 1.4-and 18-nm gold particles in rats. Small, 2008, 4(12), 2108-2111.
124. Myllynen, P.K.; Loughran, M.J.; Howard, C.V.; Sormunen, R.; Walsh, A.A.; Vähäkangas, K.H. Kinetics of gold nanoparticles in the human placenta. Reprod. Toxicol., 2008, 26(2), 130-137.
125. Wick, P.; Malek, A.; Manser, P.; Meili, D.; Maeder-Althaus, X.; Diener, L.; Diener, P.A.; Zisch, A.; Krug, H.F.; von Mandach, U. Barrier capacity of human placenta for nanosized materials. Environ. Health Perspect., 2010, 118(3), 432-436.
126. Gatti, A.M.; Gambarelli, G.D.; Gazzolo, D.; Gaetti, A.; Capitani, F.; Laboratory of Biomaterials, Department of Neurosciences, University of Modena and Reggio Emilia: Vienna, 2007, pp. 1-13.
127. Menjoge, A.R.; Navath, R.S.; Asad, A.; Kannan, S.; Kim, C.J.; Romero, R.; Kannan, R.M. Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. Biomaterials, 2010, 31(18), 5007-5021.
128. Schmidt, W. The amniotic fluid compartment: the fetal habitat. Adv. Anat. Embryol. Cell Biol., 1992, 127, 1-100.
129. Bhabra, G.; Sood, A.; Fisher, B.; Cartwright, L.; Saunders, M.; Evans, W.H.; Surprenant, A.; Lopez-Castejon, G.; Mann, S.; Davis, S.A.; Hails, L.A.; Ingham, E.; Verkade, P.; Lane, J.; Heesom, K.; Newson, R.; Case, C.P. Nanoparticles can cause DNA damage across a cellular barrier. Nat. Nanotechnol., 2009, 4(12), 876-883.
130. Andrade, S.E.; Gurwitz, J.H.; Davis, R.L.; Chan, K.A.; Finkelstein, J.A.; Fortman, K.; McPhillips, H.; Raebel, M.A.; Roblin, D.; Smith, D.H.; Yood, M.U.; Morse, A.N.; Platt, R. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol., 2004, 191(2), 398-407.
131. Olesen, C.; Sørensen, H.T.; de Jong-van den Berg, L.; Olsen, J.; Steffensen, F.H. Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet. Gynecol. Scand., 1999, 78(8), 686-692.
132. Govender, T.; Ojewole, E.; Naidoo, P.; Mackraj, I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv., 2008, 15(8), 493-501.
133. Dean, J.C.; Hailey, H.; Moore, S.J.; Lloyd, D.J.; Turnpenny, P.D.; Little, J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet., 2002, 39(4), 251-259.
134. Perucca, E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol., 2005, 4(11), 781-786.
135. Elovitz, M.A. Anti-inflammatory interventions in pregnancy: now and the future. Semin. Fetal Neonatal Med., 2006, 11(5), 327-332.
136. Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res., 2003, 20(11), 1772-1778.
137. Nezhadi, S.H.; Choong, P.F.; Lotfipour, F.; Dass, C.R. Gelatinbased delivery systems for cancer gene therapy. J. Drug Target., 2009, 17(10), 731-738.
138. Burke, R.S.; Pun, S.H. Extracellular barriers to in vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjug. Chem., 2008, 19(3), 693-704.
139. Basarkar, A.; Singh, J. Nanoparticulate systems for polynucleotide delivery. Int. J. Nanomedicine, 2007, 2(3), 353-360.